#WorldCancerDay

At MPP, we expand access to #cancer medicines via public health–oriented licences.

In 2022, MPP signed the first-ever #voluntarylicence for a cancer medicine with @novartis.bsky.social, boosting access to nilotinib for CML with the @uiccofficial.bsky.social -led #ATOM consortium.

Around 375 patients with #chronicmyeloidleukaemia (CML) in El Salvador, Indonesia & the Philippines are now accessing quality-assured generic #nilotinib.

Made possible through a #voluntarylicence from @novartis.bsky.social to MPP via the ATOM coalition - @uiccofficial.bsky.social!

lnkd.in/eruiP-Gv

Expanding the #voluntarylicence for cabotegravir long-acting from #HIV prevention to treatment builds on 10+ years of #MPP–#ViiVHealthcare collaboration.
Founded by #Unitaid in 2010, MPP helped 23M+ access DTG—now doing the same for CAB LA with generic partners for prevention and treatment.